💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Poractant Alfa

CHEMBL1201622 Phase 4 Одобрено Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Poractant alfa is a natural porcine-derived pulmonary surfactant extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins B and C that reduces alveolar surface tension, preventing alveolar collapse during expiration. It is used for the prevention and treatment of respiratory distress syndrome (RDS) in premature neonates by restoring or supplementing deficient surfactant.

Механизм действия

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Poractant alfa is a natural porcine-derived pulmonary surfactant extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins B and C that reduces alveolar surface tension, preventing alveolar collapse during expiration. It is used for the prevention and treatment of respiratory distress syndrome (RDS) in premature neonates by restoring or supplementing deficient surfactant.

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Yes, Poractant Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201622. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.